1st Quarter - Report

EPILEPSY FOUNDATION for EPILEPSY FOUNDATION

Firm
Client
Income
—
Expenses
$155,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

-Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2024, support funding for epilepsy programs and research including $13 million for the CDCs Epilepsy program, $164 million for the Safe Motherhood and Infant Health program, $51 billion for the NIH, $10 million to start considering an epilepsy-related research and clinical consortium at the NIH, $5 million for the National Neurological Conditions Surveillance System and increased funding for the Social Security Administration. -Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024, support $23.585 million for the VA Epilepsy Centers of Excellence. -Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2024, support $3.963 billion for the Food & Drug Administrations BA. -Defense Appropriations Act, 2024, support robust funding for epilepsy-related research through the Congressionally Directed Medical Research Programs.

LobbyistCovered position, as disclosed
TYLER BECK —
RACHEL PATTERSON —
LAURA WEIDNER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

-S. 652/H.R. 2630, Safe Step Act, support passage. -Identify and make recommendations on improvements to federal law for safe and legal access to medical cannabis and medical cannabis products.

LobbyistCovered position, as disclosed
TYLER BECK —
RACHEL PATTERSON —
LAURA WEIDNER —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2630 (118th), S. 652 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.